Sangamo BioSciences, Inc. has signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. The acquisition is expected to close in September, subject to customary closing conditions.    Sangamo will receive more than 120 issued, pending or in-licensed patents that include the AAV vector platform and manufacturing methods, therapeutic transgenes, and technology for direct administration of AAV to...